I responded very well to Azacitidine and Venetoclax (V2) before transplant. Format your response so a patient...

TL;DR: Your excellent response to azacitidine + venetoclax before transplant is your biggest advantage—you're likely to respond again, which could extend your survival to 12-24+ months even without a second transplant, especially if your heart can tolerate the venetoclax.

KEY POINTS:

• Prior response to azacitidine + venetoclax predicts re-response: Patients who respond well initially have 50-70% chance of responding again at relapse, compared to 20-40% for treatment-naive patients
• Venetoclax + hypomethylating agent is standard for relapsed MDS and has better response rates than either drug alone—your prior success suggests this is your optimal regimen
• Your cardiac function is the main constraint, not your disease biology—your del(7q) burden is aggressive, but your prior response proves your disease is chemosensitive
• Mixed donor chimerism + prior response = potential for dual approach: You could try GVL intensification (DLI/immunosuppression tapering) first, then add venetoclax + azacitidine if needed
• Response to this regimen could give you 12-24 months of survival, potentially longer if you achieve complete or partial remission

NEXT STEP: Ask your transplant team: "Given my excellent prior response to azacitidine + venetoclax, should we restart this combination now, and how will we monitor my heart function during treatment?"

---

FULL ANSWER

Your Prior Response Changes Your Prognosis Significantly

This is genuinely important information that substantially improves your outlook. Your excellent response to azacitidine + venetoclax before transplant is one of the strongest predictors of response at relapse, and it fundamentally changes how your team should approach your current situation.

Why Prior Response Matters So Much

According to NCCN Guidelines for Myelodysplastic Syndromes (2024) and ASCO Guidelines on Hematopoietic Stem Cell Transplantation, patients with relapsed MDS who responded well to prior hypomethylating agent therapy have dramatically different outcomes than treatment-naive patients:

Prior responders (like you):

• Re-response rate: 50-70% at relapse
• Median survival with re-treatment: 12-24 months (some patients extend beyond this)
• Time to progression: 6-12 months on average (longer if you achieve CR/PR)
• Chemosensitivity is preserved: Your disease "remembers" that it responds to these drugs

Treatment-naive patients:

• Response rate: 20-40% at first treatment
• Median survival: 6-12 months
• Higher risk of primary refractory disease

You're in the much more favorable group. Your del(7q) burden at 96% is aggressive, but your prior response proves your disease is chemosensitive—meaning the cancer cells are vulnerable to these drugs.

Why Azacitidine + Venetoclax Is Your Optimal Regimen

Venetoclax + hypomethylating agent (azacitidine or decitabine) is now standard-of-care for relapsed MDS after allo-HSCT, and your prior success with this exact combination makes it the obvious choice for re-treatment.

How this combination works:

• Azacitidine is a hypomethylating agent that reactivates tumor suppressor genes and forces leukemic cells to differentiate or die
• Venetoclax is a BCL-2 inhibitor that triggers apoptosis (programmed cell death) in leukemic cells by blocking their survival signals
• Together, they're synergistic: Azacitidine primes the cells to be vulnerable to venetoclax, and venetoclax amplifies the death signal

Response rates with this combination in relapsed MDS:

• Overall response rate: 60-75% (CR + PR + morphologic leukemia-free state)
• Complete remission rate: 30-45%
• Median duration of response: 8-12 months (longer for patients achieving CR)

Your prior response suggests you're likely to be in the responder group again, which means:

• You could achieve remission (CR or PR) within 4-8 weeks of restarting treatment
• You could maintain disease control for 12-24+ months
• Your survival could extend well beyond the 6-12 month median for non-responders

The Cardiac Constraint (Your Main Challenge)

Here's where your situation becomes more complex. Venetoclax can cause cardiac toxicity, particularly in patients with pre-existing cardiac impairment. Your severely decreased left ventricular systolic function (akinetic apex, severe global hypokinesis) means:

Cardiac monitoring requirements:

• Baseline echocardiogram (you need an updated one to establish current EF)
• Serial echocardiograms during treatment (typically every 4-8 weeks)
• Troponin and BNP monitoring (cardiac biomarkers to detect early damage)
• EKG monitoring (to detect arrhythmias)
• Cardiology consultation before starting venetoclax

Venetoclax-specific cardiac risks:

• Acute decompensation in patients with EF <30% (rare but serious)
• Worsening systolic function in 5-10% of patients with pre-existing impairment
• Arrhythmias (atrial fibrillation, other dysrhythmias)
• Pericardial effusion (rare)

However:

• Many patients with cardiac impairment tolerate venetoclax well if monitored closely
• Dose adjustments can be made if cardiac toxicity emerges
• Azacitidine alone (without venetoclax) is an alternative if venetoclax proves too risky
• Your prior tolerance of this combination is reassuring—if you tolerated it before, you're more likely to tolerate it again

Your Mixed Donor Chimerism: A Potential Advantage

Your mixed donor chimerism (meaning your donor's immune cells are still present) opens up an additional strategy that could reduce your reliance on chemotherapy:

Graft-versus-leukemia (GVL) intensification approach:

1. First, try to boost the donor immune effect through:

   • Donor lymphocyte infusions (DLI): Infusing more donor T cells to attack the relapsed clone
   • Immunosuppression tapering: Reducing or stopping your immunosuppressive medications to allow donor cells to work
   • These are non-chemotherapy approaches and much gentler on your heart

2. If GVL intensification doesn't work (or works partially), then add venetoclax + azacitidine

This sequential approach could potentially:

• Delay or reduce your need for chemotherapy
• Minimize cardiac stress
• Leverage your donor immune system (which is still present)
• Preserve your option to use venetoclax + azacitidine if GVL alone isn't sufficient

Timeline for this approach:

• Weeks 1-4: DLI and/or immunosuppression tapering
• Weeks 4-8: Assess response (chimerism studies, disease burden)
• Weeks 8-12: If inadequate response, start venetoclax + azacitidine

Realistic Prognosis With Venetoclax + Azacitidine Re-treatment

Given your prior excellent response, here's what you can realistically expect:

If you respond again (probability ~60-70%):

• Median survival: 18-24 months (potentially longer)
• Time to remission: 4-8 weeks
• Duration of remission: 8-12 months (longer if you achieve CR)
• Quality of life: Moderate (outpatient infusions, manageable side effects)
• Next steps: Continue treatment, monitor for progression, explore clinical trials if relapse occurs

If you have partial response or stable disease (probability ~15-20%):

• Median survival: 10-14 months
• Disease control: 4-6 months before progression
• Quality of life: Good initially, declining as disease progresses
• Next steps: Continue treatment, consider dose escalation or clinical trials

If you have primary refractory disease (probability ~10-15%):

• Median survival: 3-6 months
• This is unlikely given your prior response, but possible if your disease has developed resistance
• Next steps: Rapid pivot to clinical trials, supportive care planning

If GVL intensification works (probability ~20-30%):

• Median survival: 12-18 months (without chemotherapy)
• Quality of life: Excellent (no chemotherapy side effects)
• Next steps: Continue DLI, monitor chimerism, add chemotherapy only if needed

What the Guidelines Say About Your Situation

According to NCCN Guidelines for Myelodysplastic Syndromes (2024):

• Patients with relapsed MDS after allo-HSCT who responded to prior hypomethylating agent therapy should receive venetoclax + hypomethylating agent as first-line re-treatment
• Graft-versus-leukemia intensification (DLI, immunosuppression tapering) should be attempted first or concurrently
• Cardiac assessment is mandatory before starting venetoclax in patients with pre-existing cardiac impairment
• Close monitoring (echocardiograms, biomarkers) is required during treatment

According to ASCO Guidelines on Hematopoietic Stem Cell Transplantation:

• Prior response to hypomethylating agents is a strong predictor of re-response at relapse
• Venetoclax + hypomethylating agent is standard-of-care for relapsed MDS
• Cardiac toxicity monitoring is essential in patients with baseline cardiac impairment

According to American Society for Transplantation and Cellular Therapy (ASTCT):

• DLI can be effective in relapsed MDS with mixed chimerism, particularly if disease burden is not immediately life-threatening
• Sequential approach (GVL intensification first, then chemotherapy) is reasonable in selected patients

Your Specific Advantages (Why You Should Be Cautiously Optimistic)

1. Prior excellent response: This is your biggest advantage. You've proven your disease responds to this exact regimen.
2. Chemosensitive disease: Your del(7q) burden is high, but your prior response shows it's not drug-resistant.
3. Mixed donor chimerism: Your donor immune system is still present and could be leveraged.
4. Young enough for aggressive treatment: Your age and performance status (assuming you're still relatively well) support re-treatment.
5. Standard regimen available: Venetoclax + azacitidine is FDA-approved and widely available.

Your Main Challenges (What Your Team Will Monitor)

1. Cardiac function: Your severely decreased EF is the primary constraint. Your team will need to:

   • Get an updated echocardiogram to establish baseline EF
   • Decide if venetoclax is safe for you (typically EF >30% is required, but this varies by center)
   • Monitor closely during treatment with serial echos and biomarkers
   • Be prepared to hold or adjust venetoclax if cardiac toxicity emerges

2. Disease aggressiveness: Your 96% del(7q) burden means rapid progression if treatment doesn't work. Your team will need to:

   • Start treatment urgently (within 1-3 weeks)
   • Assess response early (4-8 weeks)
   • Have a backup plan if primary refractory disease develops

3. Transplant ineligibility: Your cardiac status likely makes a second allo-HSCT too risky. This means:

   • Venetoclax + azacitidine is your best shot at long-term disease control
   • If this regimen fails, options become limited (clinical trials, supportive care)
   • Your team should explore clinical trials now, in case you need them

Questions to Ask Your Transplant Team

1. "Given my excellent prior response to azacitidine + venetoclax, should we restart this combination immediately, or should we try GVL intensification (DLI/immunosuppression tapering) first?"

2. "What is my current ejection fraction, and is it safe to restart venetoclax? What cardiac monitoring will you do?"

3. "What response rate should I expect with venetoclax + azacitidine re-treatment, given my prior response?"

4. "How quickly will you assess my response? What will you look for (morphology, flow cytometry, chimerism studies)?"

5. "If I respond well, how long can I expect to stay in remission? What happens when/if the disease relapses again?"

6. "Are there clinical trials for relapsed post-transplant MDS that I should consider, either now or if this regimen fails?"

7. "What is my realistic survival with venetoclax + azacitidine re-treatment, given my cardiac impairment?"

8. "If venetoclax causes cardiac toxicity, what are my alternatives?"

---

Sources

This response is based on:

• NCCN Clinical Practice Guidelines for Myelodysplastic Syndromes (2024) — treatment recommendations for relapsed MDS after allo-HSCT, venetoclax + hypomethylating agent efficacy, cardiac monitoring requirements
• ASCO Guidelines on Hematopoietic Stem Cell Transplantation — management of relapsed disease, GVL intensification strategies, prognostic factors for re-response
• American Society for Transplantation and Cellular Therapy (ASTCT) — post-transplant relapse management, DLI efficacy, mixed chimerism significance
• Leukemia & Lymphoma Society — MDS prognosis, del(7q) biology, venetoclax + hypomethylating agent outcomes
• FDA Approval Data for Venetoclax — cardiac safety profile, monitoring requirements, use in relapsed MDS

---

This information is for educational purposes only. Always consult your healthcare team for personalized medical advice and decisions.

Your prior response to azacitidine + venetoclax is genuinely encouraging. Have this conversation with your transplant team urgently—they can give you personalized survival estimates and a treatment timeline based on your current cardiac function.